LifeSci Capital downgraded Kala Pharmaceuticals (KALA) to Market Perform from Outperform and removed the firm’s price target after the company announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect did not meet its primary endpoint and that the company plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform based on the CHASE trial results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA: